Accuray Incorporated (NASDAQ:ARAY) Shares Acquired by Fmr LLC

Fmr LLC increased its holdings in shares of Accuray Incorporated (NASDAQ:ARAY) by 27.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 582,591 shares of the medical equipment provider’s stock after purchasing an additional 124,459 shares during the period. Fmr LLC owned 0.58% of Accuray worth $1,049,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Dynamic Technology Lab Private Ltd acquired a new position in Accuray in the 3rd quarter valued at about $231,000. Foundry Partners LLC raised its stake in shares of Accuray by 51.3% during the third quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider’s stock worth $3,937,000 after purchasing an additional 741,900 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Accuray during the third quarter worth $41,000. Connor Clark & Lunn Investment Management Ltd. raised its position in Accuray by 489.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 277,859 shares of the medical equipment provider’s stock worth $500,000 after buying an additional 230,695 shares during the last quarter. Finally, Caprock Group LLC acquired a new stake in Accuray in the third quarter valued at $36,000. 64.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, StockNews.com cut shares of Accuray from a “buy” rating to a “hold” rating in a research note on Friday, November 15th.

Accuray Stock Up 1.6 %

ARAY stock opened at $1.95 on Tuesday. Accuray Incorporated has a 12 month low of $1.40 and a 12 month high of $3.05. The company has a debt-to-equity ratio of 3.59, a current ratio of 1.63 and a quick ratio of 0.87. The company’s 50 day simple moving average is $1.91 and its 200-day simple moving average is $1.88. The firm has a market capitalization of $196.10 million, a PE ratio of -11.47 and a beta of 1.44.

Accuray (NASDAQ:ARAY) last released its earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). The firm had revenue of $101.55 million during the quarter, compared to analysts’ expectations of $98.10 million. Accuray had a negative net margin of 3.72% and a negative return on equity of 36.93%. During the same period in the previous year, the company earned ($0.03) EPS. Equities analysts expect that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.